Aim. To examine efficacy of polychemotherapy (PCT) CHOP-21 in patients with diffuse large B-cell lymphosarcoma (DLBCL). Material and methods. Fifty-five DLBCL patients received first-line therapy according to CHOP-21 program in 1996-2004. The diagnosis was made by WHO criteria. Results. Initially, 37 patients had lymph node lesions, 18 - nonlymphatic lesions. Complete remissions were achieved in 49% (56.7% in nodal lesions, 33.3% in extranodal ones). Overall 5-year survival was 35%, event-free - 25%, for patients with nodal lesions - 36 and 32%, respectively, extranodal lesions - 35 and 22%, respectively. Overall 5-year and event-free survival in patients with local lesions was 85 and 75%, generalized - 25 and 20%, respectively. In patients with involvement of the gastrointestinal tract 3-year overall and event-free survival reached 50 and 45%. Event-free survival was not seen in patients with extranodal lesions of other locations in overall 3-year survival 45%. Conclusion. PCT program CHOP-21 was effective in DLBCL patients with local nodular lesions except cases with large-size tumors, invasion in the adjacent organs and tissues and isolated gastric lesion.
|Number of pages||4|
|Publication status||Published - Aug 22 2005|
- Diffuse large B-cell lymphosarcoma
- Generalized lesion
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism